Focus on Equities that offer Growth,
Value and Strong Potential Return
Monday, November 30, 2015

AcelRx Pharmaceuticals, Inc.

In-Depth Research Report Available for ACRX

Download Free Report Now

Company Profile ACRX

On September 22, 2015, AcelRx announced that the European Commission (EC) approved Zalviso™ (sufentanil sublingual tablet system) for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting. Going forward ... (see research report)

News & Events ACRX